Saturday 21 Dec, 2024 09:15 PM
Site map | Locate Us | Login
   Can Fin Homes CFO Apurav Agarwal resigns    Auro Pharma gets UK MHRA nod for cancer drug    Reliance Inds arm to acquire 45% stake in Health Alliance Group    Mazagon Dock Shipbuilders delivers two warships to Indian Navy    Dalmia Bharat's president Rajiv Bansal resigns    Cupid bags order worth Rs 18-cr from UNFPA    NTPC Green inks MoU with Govt of Bihar    IDBI Bank board to mull fund-raising proposal on Dec 31    NRB Industrial Bearings CFO Gulestan Kolah resigns    Shilpa Medicare gets GMP certification for Hyderabad Facility    Siemens Ltd leads losers in 'A' group    Restaurant Brands Asia to raise Rs 500 crore via QIP    NBCC bags orders worth Rs 298 cr for healthcare infrastructure projects    Tantia Constructions Ltd leads losers in 'B' group    Volumes soar at Aegis Logistics Ltd counter 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Auro Pharma gets UK MHRA nod for cancer drug
21-Dec-24   15:20 Hrs IST

Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for intravenous infusion.

Bevacizumab is used in the treatment of various cancers, including metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell carcinoma, cervical cancer, epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.

The pharma major reported a 7.95% rise in consolidated net profit to Rs 817.38 crore on a 6.93% increase in revenue from operations to Rs 7,646.21 crore in Q2 FY25 over Q2 FY24.

Shares of Aurobindo Pharma fell 1.17% to close at Rs 1,240.70 on Friday, 20 December 2024.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures |DP Closure| |Rights & Obligations-English| Rights & Obligations-தமிழ் | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking Hit Count : 37668847
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd